What we do
We identify, build and invest in innovative Nordic startup companies founded on strong science, with the ultimate goal of developing products that can transform patient treatment.
We identify, build and invest in innovative Nordic startup companies founded on strong science, with the ultimate goal of developing products that can transform patient treatment.
Collaborating with outstanding researchers, academic institutions, entrepreneurs and leaders in the biotech and pharma industry, we provide capital, network and know-how to transform promising life-science discoveries into successful biotech startups.
We focus on company creation and building biotech startups in the Nordic region. We aim to develop strong and competitive companies that we finance all the way to a commercial exit.
In 2020, we made eight investments in new companies, and we currently have 32 portfolio companies. In the coming years, we will continue to increase our investments activities in the Nordics.
Through our hands-on approach, we ensure that promising projects and startup companies have the optimal conditions for success.
Acesion Pharma develops new treatments for the acute cardioversion of artrial fibrillation.
Galecto focuses on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases.
Reapplix develops a device that produces a fully autologous dressing for wound healing.
Avilex Pharma develops dimeric peptides that target PSD95 for the treatment of neuropathic pain.
IO Biotech is a clinical stage biotech company developing distruptive immune therapies for immunological treatment of cancer.
Inthera Bioscience is a Swiss biotech company targeting HPV+ head and neck cancer (HNSCO) and/or HPV+ genitourinary cancer as initial indication(s).
Biosyntia is a biotech startup within synthetic biology and metabolic engineering. Biosyntia develops biocatalysts at an unprecedented speed and efficiency by employing a patent pending high-throughput screening technology.
NMD Pharma is developing novel treatments for Neuromuscular diseases such as Myasthenia gravis and ALS. The company is in preclinical development.
CorWave is a French medtech company, developing a new generation of LVADs (Left Ventricle Assist Device).
Heparegenix GmbH is a German company developing a new treatment to promote liver regeneration.
AMRA is a healthcare IT start-up. The company is developing an automated image analysis platform for a full body MRI scan. The platform will be able to quantify fat and muscle volumes across the body.
The company is developing a new therapeutic protein for the treatment of neuropathic pain.
AFYX Therapeutics is changing the way mucosal diseases are treated. We are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options.
The team has developed an expertise around the role of GIP (Gastric inhibitory polypeptide) in diabetes and obesity. ANTAG is based at the University of Copenhagen.
NorthSea Therapeutics is developing icosabutate a first-in-class Structurally Engineered Fatty Acid (SEFA) for Non-Alcoholic SteatoHepatitis or NASH. In addition, NorthSea is evaluating the potential of various SEFAs in other metabolic, inflammatory and fibrotic diseases.
Developing molecules that uniquely modulate the synaptic vesicle protein SV2A.
BioPhero is a biotech spin-out from the Technical University of Denmark. The company is a pioneer in providing multiple bio-based pheromones for pest management. Agriculture is in a transition period where BioPhero is providing a sustainable solution.
Precirix is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments.
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compounds that sensitizes the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response.
current portfolio companies.
projects and companies reviewed since 2007.
exits since 2007.
Novo Seeds is comprised of a team of passionate investment professionals, dedicated to working with scientists and entrepreneurs to build biotech companies in the Nordics.
The Novo Seeds team is based at our headquarters in Copenhagen, Denmark.
Novo Holdings A/S
Tuborg Havnevej 19
2900 Hellerup
Denmark
+45 3527 6500
CVR# 24257630